Amundi Trims Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Amundi lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 5.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,154,826 shares of the medical equipment provider's stock after selling 71,482 shares during the quarter. Amundi owned approximately 0.58% of Zimmer Biomet worth $117,261,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Dunhill Financial LLC grew its position in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 218 shares during the period. Stonebridge Financial Group LLC bought a new position in Zimmer Biomet during the fourth quarter valued at about $25,000. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet during the third quarter worth about $28,000. Brooklyn Investment Group bought a new position in Zimmer Biomet during the third quarter worth about $35,000. Finally, Kentucky Trust Co bought a new position in Zimmer Biomet during the fourth quarter worth about $39,000. Institutional investors own 88.89% of the company's stock.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.95% of the stock is currently owned by insiders.

Remove Ads

Zimmer Biomet Stock Performance

NYSE:ZBH traded up $3.60 during trading hours on Thursday, reaching $107.63. The company had a trading volume of 2,062,515 shares, compared to its average volume of 1,921,875. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The firm has a market cap of $21.43 billion, a PE ratio of 24.19, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The business's 50 day moving average price is $105.72 and its 200-day moving average price is $107.06. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the firm earned $2.20 earnings per share. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio is presently 21.57%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ZBH shares. Stifel Nicolaus increased their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research report on Thursday, January 23rd. Royal Bank of Canada cut their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. JMP Securities reiterated a "market outperform" rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Truist Financial reiterated a "hold" rating and set a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.